Диссертация (Разработка технологий получения рекомбинантного тимозина бета-4 человека и его аналогов), страница 20
Описание файла
Файл "Диссертация" внутри архива находится в папке "Разработка технологий получения рекомбинантного тимозина бета-4 человека и его аналогов". PDF-файл из архива "Разработка технологий получения рекомбинантного тимозина бета-4 человека и его аналогов", который расположен в категории "". Всё это находится в предмете "химия" из Аспирантура и докторантура, которые можно найти в файловом архиве РТУ МИРЭА. Не смотря на прямую связь этого архива с РТУ МИРЭА, его также можно найти и в других разделах. Архив можно найти в разделе "остальное", в предмете "диссертации и авторефераты" в общих файлах, а ещё этот архив представляет собой кандидатскую диссертацию, поэтому ещё представлен в разделе всех диссертаций на соискание учёной степени кандидата химических наук.
Просмотр PDF-файла онлайн
Текст 20 страницы из PDF
Chen, Aaron Choi,Jessica R. Ong, Paul D. Benya, Hanna Mikkola, M. Luisa Iruela-Arispe, Karen M. Lyons // PloSone. – 2012. – V. 7. – №. 2. – P. e30562104) Role of thymosin beta 4 in hair growth / X.Y. Gao, F. Hou, Z.P. Zhang, M.T. Nuo, H.Liang, M. Cang, Z.G. Wang, X. Wang, T. Xu, L.Y. Yan, X.D. Guo, D.J. Liu // MolecularGenetics and Genomics. – 2016. – P. 1-8.105) Thymosin beta4 mediated PKC activation is essential to initiate the embryoniccoronary developmental program and epicardial progenitor cell activation in adult mice in vivo /Ildiko Bock-Marquette, Santwana Shrivastava, G.C. Teg Pipes, Jeffrey E.
Thatcher, AllissaBlystone, John M. Shelton, Cristi L. Galindo, Bela Melegh, Deepak Srivastava, Eric N. Olson, J.Michael DiMaio // Journal of molecular and cellular cardiology. – 2009. – V. 46. – №. 5. – P.728-738.91106) Thymosin beta4 is an essential paracrine factor of embryonic endothelial progenitorcell-mediated cardioprotection / Rabea Hinkel, Chiraz El-Aouni, Tonia Olson, Jan Horstkotte,Stefan Mayer, Sebastian Müller, Michael Willhauck, Christine Spitzweg, Franz-Josef Gildehaus,Wolfgang Münzing, Ewald Hannappel, Ildiko Bock-Marquette, J.
Michael DiMaio, Antonis K.Hatzopoulos, Peter Boekstegers and Christian Kupatt // Circulation. – 2008. – V. 117. – №. 17. –P. 2232-2240.107) Pipes, G. T. Cardioprotection by systemic dosing of thymosin beta four followingischemic myocardial injury/ G. T. Pipes //Frontiers in pharmacology. – 2013. – V. 4. – P. 149.108) Stimulation of adult resident cardiac progenitor cells by durable myocardialexpression of thymosin beta 4 with ultrasound-targeted microbubble delivery / S. Chen, M.Shimoda, J. Chen, P.A. Grayburn // Gene therapy. – 2013.
– V. 20. – №. 2. – P. 225-233.109) Adeno-associated viral vector 2.9 thymosin ss4 application attenuates rejection afterheart transplantation: results of a preclinical study in the pig / Johannes Postrach, MaximilianSchmidt, Michael Thormann, Eckart Thein, Lars Burdorf, Bruno Reichart, Karl Sotlar, ChristophWalz, Claudius Faber, Andreas Bauer, Michael Schmoeckel, Christian Kupatt, Rabea Hinkel //Transplantation. – 2014. – V.
98. – №. 8. – P. 835-843110) Chiu, L.L. Controlled release of thymosin beta4 using collagen- chitosan compositehydrogels promotes epicardial cell migration and angiogenesis / L.L. Chiu, M. Radisic // Journalof controlled release. – 2011. – V. 155. – №. 3. – P.
376-385.111) Cardiac tissue engineering: current state and perspectives / L.L. Chiu, R.K. Iyer, L.A.Reis, S.S. Nunes and M. Radisic// Frontiers in bioscience (Landmark edition). – 2011. – V. 17. –P. 1533-1550.112) Controlled release of thymosin Beta 4 using a collagen-chitosan sponge scaffoldaugments cutaneous wound healing and increases angiogenesis in diabetic rats with hindlimbischemia / Dongdong Ti, Haojie Hao, Lei Xia, Chuan Tong, Jiejie Liu, Liang Dong, Shenjun Xu,Yali Zhao, Huiling Liu, Xiaobing Fu and Weidong Han // Tissue Engineering Part A. – 2014. –V. 21. – №.
3-4. – P. 541-549.113) Controlled release of thymosin beta4 from injected collagen- chitosan hydrogelspromotes angiogenesis and prevents tissue loss after myocardial infarction / L.L. Chiu, L.A.Reis, A. Momen, M. Radisic // Regenerative medicine. – 2012. – V. 7. – №. 4. – P. 523-533.114) Human embryonic stem cell-derived microvascular grafts for cardiac tissuepreservation after myocardial infarction / Thomas P.
Kraehenbuehl, Lino S. Ferreira, Alison M.Hayward, Matthias Nahrendorf, André J. van der Vlies, Eliza Vasile, Ralph Weissleder, RobertLanger, Jeffrey A. Hubbell // Biomaterials. – 2011. – V. 32. – №. 4. – P. 1102-1109.92115) Thymosin beta4 increases the potency of transplanted mesenchymal stem cells formyocardial repair / L.Ye, P. Zhang, S.
Duval, L. Su, Q. Xiong and J. Zhang // Circulation. –2013. – V. 128. – №. 11 suppl 1. – P. S32-S41.116) Perfusable branching microvessel bed for vascularization of engineered tissues / L. L.Chiu, M. Montgomery, Y. Liang, H. Liu and M. Radisic // Proceedings of the National Academyof Sciences. – 2012. – V.
109. – №. 50. – P. E3414-E3423.117) Thymosin beta4 coated nanofiber scaffolds for the repair of damaged cardiac tissue /A. Kumar, A. Patel, L. Duvalsaint, M. Desai and E.D. Marks // Journal of nanobiotechnology. –2014. – V. 12. – №. 1. – P. 1.118) Rudat, C. Wt1 and epicardial fate mapping / C. Rudat, A. Kispert // Circulationresearch.
– 2012. – V. 111. – №. 2. – P. 165-169.119) Thymosin β4. Actin Regulation and More / Elena G. Yarmola, Evguenia S.Klimenko, Go Fujita and Michael R. Bubbann // N.Y. Acad. Sci. – 2007. – V. 1112. – P. 76–85.120) Thymosin beta 4 sulfoxide is an anti-inflammatory agent generated by monocytes inthe presence of glucocorticoids / J.D. Young, A.J. Lawrence, A.G.
MacLean, P. Leung, I.B.McInnes, B. Canas, D.J. Pappin and R.D. Stevenson // Nature medicine. – 1999. – V. 5. – №. 12.– P. 1424-1427.121) Muscle injury-induced thymosin β4 acts as a chemoattractant for myoblasts / YukaTokura, Yuki Nakayama, So-ichiro Fukada, Noriko Nara, Hiroshi Yamamoto, Ryoichi Matsudaand Takahiko Hara // Journal of biochemistry. – 2011. – V. 149. – №. 1. – P. 43-48.122) beta-Thymosins, small acidic peptides with multiple functions / T. Huff, C.S. Müller,A.M.
Otto, R. Netzker and E. Hannappel // The international journal of biochemistry & cellbiology. – 2001. – V. 33. – №. 3. – P. 205-220.123) HPLCESI-MS analysis of oral human fluids reveals that gingival crevicular fluid isthe main source of oral thymosins beta(4) and beta(10) / R. Inzitari, T. Cabras, E. Pisano, C.Fanali, B. Manconi, E. Scarano, A. Fiorita, G. Paludetti, A. Manni, S. Nemolato, G. Faa, M.Castagnola, I. Messana // Journal of separation science.
– 2009. – V. 32. – №. 1. – P. 57-63.124) Oxidation of either methionine 351 or methionine 358 in alpha 1-antitrypsin causesloss of anti-neutrophil elastase activity / C. Taggart, D. Cervantes-Laurean, G. Kim, N.G.McElvaney, N. Wehr, J. Moss, R.L:Levine // Journal of Biological Chemistry. – 2000.
– V. 275.– №. 35. – P. 27258-27265.125) β-thymosins and interstitial lung disease: study of a scleroderma cohort witha one-year follow-up / Maria De Santis, Rosanna Inzitari, Silvia L. Bosello, Giusy Peluso,Chiara Fanali, Federica Iavarone, Gaetano Zizzo, Mario Bocci, Tiziana Cabras, Irene Messana,93Leo Fuso, Francesco Varone, Gabriella Pagliari, Massimo Castagnola and Gianfranco Ferraccioli// Respiratory research. – 2011.
– V. 12. – №. 1. – P. 1.126). Goldstein, A.L. Advances in the basic and clinical applications of thymosin β4 / A.L.Goldstein , H.K. Kleinman // Expert opinion on biological therapy. – 2015. – V. 15. – №. sup1. –P. 139-145.127) N-Acetyl-Seryl-Aspartyl-Lysyl-Proline (Ac-SDKP) Delays the Development ofHypertension and Renal Damage in Systemic Lupus Erythematosus (SLE) / Pablo Nakagawa, TD. Liao, M. Worou, H. Basha, E.
Peterson, B. Janic, X-P. Yang, N-E. Rhaleb and OscarCarretero. // The FASEB Journal. – 2015. – V. 29. – №. 1 Supplement. – P. 667.7.128) N-Acetyl-Seryl-Aspartyl-Lysyl-Proline: mechanisms of renal protection in mousemodel of systemic lupus erythematosus / Tang-Dong Liao, Pablo Nakagawa, Branislava Janic,Martin D’Ambrosio, Morel E. Worou, Edward L. Peterson, Nour-Eddine Rhaleb, Xiao-PingYang, Oscar A. Carretero // American Journal of Physiology-Renal Physiology.
– 2015. – V.308. – №. 10. – P. F1146-F1154.129) High plasma level of N-acetyl-seryl-aspartyl-lysyl-proline: a new marker of chronicangiotensin-converting enzyme inhibition / M. Azizi, E. Ezan, L. Nicolet, J. M. Grognet and J.Menard // Hypertension. – 1997. – V. 30. – №. 5. – P. 1015-1019.130) Prolyly oligopeptidase is involved in release of the anti fibrotic peptide As-SDKP /M. A.Cavasin, N.E.
Rhaleb, X.P. Yang and O.A. Carretero // Hypertension. – 2004. – V. 43. –№. 5. – P. 1140-1145.131) Reduction of cardiac fibrosis decreases systolic performance with an affect ondiastolic function in hypertensive rats / O.H. Cingolani, X-P. Yang, Y-H. Liu, M. Villanueva, N.E. Rhaleb and O.A.
Carretero // Hypertension. – 2004. – V. 43. – №. 5. – P. 1067-1073.132) Inhibition of human bone marrow progenitors by the synthetic tetrapeptide AcSDKP /M. Guigon, D. Bonnet, F.M. Lemoine, L. Kobari, C. Permentier, J.Y. Mary and A. Najman //Experimental hematology. – 1990. – V. 18. – №. 10. – P. 1112-1115.133) Decreased endogenous levels of Ac- SDKP promote organ fibrosis / M.A. Cavasin,T.D. Lioa, X.Z.P. Yang, J.J. Yang and O.A.
Carretero // Hypertension. – 2007. – V. 50. – №. 1. –P. 130-136.134) AcSDKP reverses inflamma- tion and fibrosis in rats with heart failure aftermyocardial infarction / F. Yang, X.P. Yang, Y.H. Liu, J. Xu, O. Cingolani, N.E. Rhaleb andO.A.
Carretero // Hypertension. – 2004. – V. 43. – №. 2. – P. 229-236.135) N-acetyl-seryl-aspartyl-lysyl-proline inhibits DNA synthesis in hu- man mesangialcells via upregulation of cell cycle modulators / K. Kanasaki, M. Haneda, T. Sugimoto, K.94Shibya, M. Isono, K. Isshiki, S. Araki, T. Uzu, A. Kashiwagi and D. Koya // Biochemical andbiophysical research communications. – 2006. – V. 342. – №. 3. – P. 758-765.136) Prevention of aortic fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in angiogentisnII-induced hypertension / C.X. Lin, N.E. Rhaleb, X.P. Yang, T.D.
